Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacyursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs' are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The March 2010 class review is on calcium channel blockers for injection and the monograph topics are on tocilizumab, capsaicin 8% patch, olanzapine extended-release injectable, von Willebrand factor/coagulation factor VIII complex, and pirfenidone. The DUE is on tocilizumab.
展开▼
